Published in Eur Urol on October 15, 2010
The impact of tumour size on the probability of synchronous metastasis and survival in renal cell carcinoma patients: a population-based study. BMC Urol (2014) 1.44
Correcting the Shrinkage Effects of Formalin Fixation and Tissue Processing for Renal Tumors: toward Standardization of Pathological Reporting of Tumor Size. J Cancer (2015) 0.86
Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index. Korean J Urol (2011) 0.82
Serum and urine biomarkers for human renal cell carcinoma. Dis Markers (2015) 0.80
Nephrectomy or nephron-sparing surgery - how to decide? Contemp Oncol (Pozn) (2013) 0.78
Application of the revised Tumour Node Metastasis (TNM) staging system of clear cell renal cell carcinoma in eastern China: advantages and limitations. Asian J Androl (2013) 0.75
Kidney cancer: Are we overclassifying renal cancer? Nat Rev Urol (2010) 0.75
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol (2009) 5.62
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol (2006) 4.98
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res (2007) 2.47
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm. Eur Urol (2006) 2.11
Important aspects of organ-preserving surgery for renal tumors: indications, new standards, and oncological outcomes. Dtsch Arztebl Int (2009) 2.05
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol (2008) 2.02
Guidelines on bladder cancer. Eur Urol (2002) 1.97
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol (2005) 1.93
Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol (2006) 1.86
Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int (2006) 1.85
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol (2008) 1.71
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
[Aphasia--when the system fails just as much as the language]. Tidsskr Nor Laegeforen (2014) 1.66
Short-term functional and oncologic outcomes of nephron-sparing surgery for renal tumours ≥ 7 cm. Eur Urol (2011) 1.63
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. Clin Chem (2011) 1.59
Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res (2006) 1.52
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression. Chem Biol (2005) 1.47
Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol (2004) 1.44
Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014. World J Urol (2014) 1.41
No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol (2013) 1.40
Prenatal diagnosis of congenital mesoblastic nephroma associated with renal hypertension in a premature child. Int J Urol (2004) 1.39
Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. Eur Urol (2010) 1.39
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia (2010) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol (2004) 1.33
Treatment of localised renal cell carcinoma. Eur Urol (2011) 1.29
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs (2006) 1.28
EAU guidelines on laser technologies. Eur Urol (2012) 1.27
Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol (2006) 1.27
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate (2009) 1.25
Detection of bacteria by fluorescence in situ hybridization in culture-negative soft tissue filler lesions. Dermatol Surg (2009) 1.23
Surgical treatment in cocaine body packers and body pushers. Int J Colorectal Dis (2007) 1.23
Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol (2011) 1.21
Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection. BMC Infect Dis (2002) 1.20
Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol (2012) 1.20
MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol (2008) 1.18
Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer (2010) 1.18
Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg (2005) 1.14
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer (2012) 1.14
The genomic landscape of meiotic crossovers and gene conversions in Arabidopsis thaliana. Elife (2013) 1.12
Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol (2006) 1.12
Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer (2013) 1.10
Giant hydronephrosis mimicking progressive malignancy. BMC Urol (2003) 1.10
The German S3 guideline prostate cancer: aspects for the radiation oncologist. Strahlenther Onkol (2010) 1.09
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther (2012) 1.08
External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery. World J Urol (2010) 1.08
Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial. Eur Urol (2002) 1.06
Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res (2006) 1.06
RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer (2007) 1.06
Localization of FOXP3-positive cells in renal cell carcinoma. Tumour Biol (2011) 1.05
Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer. World J Urol (2011) 1.03
Reversible switching between p- and n-type conduction in the semiconductor Ag10Te4Br3. Nat Mater (2009) 1.03
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep (2002) 1.02
Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer (2011) 1.02
Concern Squamous cell carcinoma of the oral cavity and the oropharynx in patients less than 40 years of age: a 20-year analysis. Head Neck Oncol (2012) 1.02
The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome. World J Urol (2012) 1.01
Metastasis of malignant melanoma in the ureter: possible algorithms for a therapeutic approach. Int J Urol (2009) 1.00
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett (2008) 1.00
A newly designed amplatz sheath decreases intrapelvic irrigation pressure during mini-percutaneous nephrolitholapaxy: an in-vitro pressure-measurement and microscopic study. J Endourol (2007) 1.00
Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci (2008) 0.99
Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One (2011) 0.99
Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist (2011) 0.99
Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. Int J Cancer (2007) 0.98
High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int (2011) 0.98